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CANINE OSTEOSARCOMA:
Characteristics and diagnosis
Of all naturally arising tumors of the dog,
osteosarcoma has been said to be a good large animal
model for the disease in humans (Khanna et al., 2006;
Paoloni and Khanna, 2008; Paoloni et al., 2009;
Withrow and Khanna, 2009). Osteosarcoma is the
primary malignant type of bone tumor of
mesenchymal origin; it commonly affects large to
giant breed dogs of older age (>7 years old)
(Dickerson et al., 2001; McNeill et al., 2007; Phillips
et al., 2007; Rosenberger et al., 2007). This tumor is
said to arise from primitive bone-forming
mesenchymal cells, which typically produce osteoid
and are highly metastatic compared to other types of
primary bone tumors, including chondrosarcoma and
fibrosarcoma (Cleton-Jansen et al., 2009; Gorlick and
Khanna, 2010). In most cases, dogs present with
clinical signs of lameness or a hard bony swelling
arising from skeletal or even from extraskeletal
locations (Carr et al., 2010; Jabara and McLeod,
1989; Kuntz et al., 1998; Langenbach et al., 1998;
Miller et al., 2006; Patnaik et al., 1976; Patnaik, 1990;
Ringenberg et al., 2000; Sato et al., 2004; Schena et
al., 1989; Thomsen and Myers, 1999; Urbiztondo et
al., 2010). Often there is no known history of trauma
prior to presentation. Tumors are highly metastatic
and metastases are predominantly observed in the
lungs, though other soft tissue and skeletal sites has
been reported.
Diagnosis is often made based on radiographic
appearance supported by cytology and histopathology
findings (Berg et al., 1990; Britt et al., 2007; Lamb et
al., 1990; LaRue et al., 1986; Straw et al., 1989).
Evaluation for lung and bone metastasis is often made
by 3-view thoracic radiographic survey and bone
scintigraphy or long-bone radiographs. Radiographic
lesions often represent a mixture of osteolytic and
osteoproductive bony activity with or without
sunburst appearance and presence of Codman's
triangle. In some advanced cases a pathological
fracture may be observed on bone survey radiographs.
However, these findings are not pathognomonic for
OS and it is essential to rule out the possibility of
other bone malignancies, benign processes, bone
infarctions, osteomyelitis or fungal infections (Boston
et al., 2010). Histopathology is the gold standard for
diagnosis of OS; this can be achieved by performing a
bone biopsy or by examination of the whole lesion
upon surgical removal. Histology grading and tumor
staging then follow to determine the aggressive nature
of the tumor; this may aid in the decision about
follow-up therapies (Kirpensteijn et al., 2002;
Loukopoulos and Robinson, 2007).
Comparative aspects of osteosarcoma in dogs and
man
As early as in the 1980s, researchers and
clinicians alike have highlighted the importance of
studying canine osteosarcoma as a model for humans
in order to understand the disease pathogenesis.
Several of the common characteristics between canine
and human osteosarcoma includes the aggressive
nature of the disease locally and highly metastatic
potentials, appearance on gross morphology and
histopathology; tumor primary sites and several
molecular genetic alterations including mutations for
common tumor suppressor and oncogenes; aberrant
expression of growth factors and their receptors (De
Maria et al., 2009; Kim et al., 2009; Kirpensteijn et
al., 2008; Paoloni et al., 2009; van Leeuwen et al.,
1997; Zhang et al., 2009). Table 1 lists comparative
aspects for canine and human osteosarcoma.
Therapeutic strategies for dogs with osteosarcoma
Two main therapy goals for dogs with OS are to
control local pain and to eradicate micrometastasis (or
slow down the process). Although evidence of
metastasis primarily in the lungs is the generally
accepted endpoint, it can vary from case to case due
to the influence of several other factors including
culture, client education, economy, facilities and
expertise. In a few cases, the dog will have to be
euthanized due to complications of the therapeutics
given, or due to deteriorating quality of life caused by
other factors. For instance, limb amputation is still not
commonly accepted practice in some cultures
(especially in several Asian and European nations). In
these cases, then, the veterinarian may advise a limb
amputation and additional therapies based on known
prognosticators, yet it is still at the client's discretion
to proceed with the recommendations or to choose
euthanasia. It gets even tougher when including
consideration of the client's economic status, as this
can affect the decision for euthanasia or lead to
declining therapies offered by the veterinarian. In
many states in the US, limb-sparing is a preferred
choice of treatment for large breed dogs, aiming
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primarily to preserve the limb and locomotion. The
limb is spared by removing the primary tumors with
limited margins and replacing them with a bone
allograft or an artificial device. This reduces the
possibility of complications that may arise in
amputation, especially in giant to large breed dogs
(Boston et al., 2007; Lascelles et al., 2005; Liptak et
al., 2006). This procedure is highly dependent on the
local extent of the primary tumor and type of bone
involved, and is not widely available.
Amputation and post-operative administration of
chemotherapy remain the gold standard for most
veterinary practices. Through the years, several
different protocols of chemotherapy have been
reported, varying according to drug delivery methods,
cytotoxic agents and delivery protocols. Common
chemotherapy agents used are platinum-based
compounds (cisplatin, carboplatin) and doxorubicin.
Radiotherapy (either external beam or radioisotopes)
may be initiated at a neo-adjunctive setting prior to
surgery to provide pain palliation for dogs with OS
where pain control can be achieved up to 2.5 months
(Boston et al., 2007; Fan et al., 2009; Mayer and
Grier, 2006; Mueller et al., 2005). Stereostatic
radiosurgery techniques or administration of bone-
targeting radiopharmaceutical agent 153Sm-EDTMP
are among other therapies available at selected
facilities with the intention of treating primary bone
tumors with more than just palliation (Farese et al.,
2004; Kvinnsland et al., 2002; Lattimer et al., 1990;
Milner et al., 1998; Moe et al., 1996). Other targeted
therapies, including the aforementioned, are under
investigation. Some of the recent advances in anti-
cancer therapies for canine OS are provided in Table
2.
Prognosis and prognosticators for "Canine
osteosarcoma
Despite the many advances in therapy and
molecular markers discovered for humans as
compared to dogs with osteosarcoma, the prognosis
still looks grim for both species. There is still no
therapy available with curative intent, although in
some cases both dogs and people appear to benefit
from primary interventions (amputation or limb-
sparing surgeries) combined with the current adjuvant
therapies, including the use of cytotoxic agents
(Bacon et al., 2008). Differences in metastatic rate
exist: while most dogs develop metastasis rapidly, a
smaller percentage of dogs have a tendency to
develop late metastasis. Researchers are still on the
lookout for factors that may contribute to these
differences. This is especially pertinent to metastatic
disease, which is considered the primary endpoint in
most cases. When there is metastasis, euthanasia is
commonly recommended for dogs. There is a need to
stratify dogs into prognostic groups by using
conventional (Table 2) and novel biomarkers in order
to provide better therapeutic options for dog owners.
Only in some cases is this relevant for the human
disease; caution is advised in translating directly from
dog to human unless research has been performed
proving a similarity.
In the year 2000, the human genome was
published and 5 years later, the dog genome was
publically released, giving ample opportunities for
researchers to exploit these genomes for
understanding disease pathogenesis including
osteosarcoma. In parallel with the genome release,
technology also evolved and more robust and high
throughput molecular equipment and methodologies
was also available. With the advent of microarray
technologies with the integration of bioinformatics,
huge amounts of data were generated for several
diseases for human and veterinary medicine.
Although there has been mounting research and
studies on gene expression profiling and molecular
alterations in human osteosarcoma, this information
are relatively at infancy for canine osteosarcoma
(O'Donoghue, L.E., 2010; Selvarajah G.T., 2009;
Paoloni M. et al., 201Ob).Although there is less to be
said and much more to be done, future well designed
prognostic studies on populations of dogs undergoing
new interventional therapies alone or in combination
with current therapies is important. One fact that we
should acknowledge is that even the best
prognosticator will probably fail in certain
circumstances and be inaccurate for a significant
number of dogs and hence continuous reporting and
reassessment of prognostication and prognosticators is
warranted.
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Table 1: Comparative aspects for osteosarcoma of the dog and man
Characteristics CANINE HUMAN
Incidence in USA >8000 cases/year 600 cases/ year
Median age Middle aged to older dogs Adolescent disease
Peak incidence 7-9 years Peak incidence at 10-20 years
Second small peak at 18-24 months
Median peak age at 7 years Median peak age at 16 years
Body weight 90%>20kg Heavy
Breed I Size Large/ giant breeds Tall people
Familiar pattern in Saint Bernard,
Rottweiler and Scottish Deerhound
Sex Males slightly more than females: ratio 1.1- Males more than females
1.5:1
Aetiology Not completely known Not completely known
Tumor sites 75% appendicular skeleton, metaphysis of Metaphysic or diaphysis of long bones (80-
long bones, mainly distal radius, proximal 90%).
humerus, distal femur and proximal and Bones of the knee joint.
distal tibia Proximal humerus (25%)
Predisposition Implants, fractures, familial tendency, bone Implants, fractures, familial tendency, bone
infarction, radiation, parasites (Dirofilaria infarction, radiation, Paget's disease
repens and Spirocerca !upi)
Clinical Signs Pain Pain, swelling, hard painful mass,
Swelling decreased joint mobility, localized
.- Hard painful mass erythema
Biochemistry Increased serum alkaline phosphatase and Increased serum alkaline phosphatase and
profile lactate dehydrogenase enzyme levels (also lactate dehydrogenase enzyme levels (also
as negative prClgnosticator) as negative prognosticator)
Diagnostic Cranio-caudal and latero-medial At least two orthogonal radiographic views
imaging radiographic. Views of the primary lesion, are required when a bone lesion is
including the joint above and below the suspected. MRI represents the primary
affected bone, are required. Computed mode of evaluation of OS in humans and
Tomography (CT) of the thorax is superior can clearly demonstrate the extent of
to radiography in detecting smaller lung tumour invasion of the surrounding soft
lesions. Nuclear bone scintigraphy for tissue, neurovascular involvement, extent of
detection of bone metastases. MRI for bone marrow replacement and presence of'
staging and planning of limb-sparing discontinuous metastases. A CT scan of the
procedures chest and a nuclear scintigraphy bone scan
are recommended to rule out metastasis to
the lungs and bone. Use of positron-
emission tomography (PET) for staging and
monitoring_ treatment.
Primary tumor Bone destruction, new bone formation, Bone destruction, new bone formation,
radiographic Codman's triangle, soft tissue swelling, Codman's triangle, soft tissue swelling,
features sunburst appearance sunburst appearance
Pathological Uncommon pathological fracture (3%) Uncommon pathological fracture (5-10%)
fractures
Karyotype 75% aneuploid, complex to chaotic. 75% aneuploid, complex to chaotic.
Gains and losses identified in many Gains and losses identified inmany
autosomes. Various centro metric autosomes and X chromosome,
trans locations and rearrangements. chromosome gains outnumber the losses by
20-30% many centrometric rearrangements.
Histological High grade High grade (central)
grade and Predominantly osteoblastic, other Predominantly osteoblastic, other
features histologies: chondroblastic, fibroblastic, histologies: chondroblastic, fibroblastic,
telangiectic telangiectic, giant cell rich. Small cell
osteosarcoma-(rare variant)
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Metastatic sites Lungs> bones> soft tissue Lungs>bones> soft tissue
90% cases with metastasis at diagnosis 20% cases metastasis at diagnosis
Therapies Amputation (Most common) Limb sparing techniques (90% of cases)
Limb sparing techniques (at specialized Amputation (rare)
centers) Neoadjuvant chemotherapy
Adjuvant chemotherapy
(Pre-operative protocol did not have
significant increase in survival as compared
to post-operative protocols)
Surgical repair Often with arthrodesis Often with modular articulating devices
Common Doxorubicin, Cisplatin, Lobaplatin, Doxorubicin, Cisplatin,
cytotoxic agents Carboplatin Methotrexate and Ifosfamide
used for -metronomic chemotherapy with
chemotherapy Doxycycline, Piroxicam and
Cyclophosphamide
Duration of 4-6 cycle of adjuvant chemotherapy Up to 1 year of adjuvant chemotherapy
adjuvant
chemotherapy
Regional lymph 4.4-9% of cases <10% of cases
node metastasis Poor prognosis Poor prognosis
Metastatic rate 90% before 1 year 80% before 2 years
without
chemotherapy
Survival 60% survival at one year post operative 70% survival at 5-year postoperative
chemotherapy. chemotherapy. 30-40% of OS patients still
experience relapses within 3 years of
treatment.
Molecular Ezrin high expression-metastasis Ezrin high expression-metastasis
genetic MMPs overexpression MMPs overexpression
alterations TP53 mutation TP53 mutation
(which promotes MET oncogene overexpression MET oncogene overexpression
tumor P-glycoprotein (chemoresistance) P-glycoprotein (chemoresistance)
aggressiveness COX2 overexpression COX2 overexpression
and correlates PTEN mutation PTEN mutation
with poor VEGF overexpression involved in VEGF overexpression involved in
prognosis) metastasis and chemoresistance metastasis and chemoresistance
Survivin overexpression Survivin overexpression
c-Fos overexpression
Rb mutation
-CXCR4 overexpression predicts metastasis
uPAI uPAR increased expression promotes
invasion
Prognostic Lung metastasis Lung metastasis
factors (poor Lymph node metastasis Lymph node metastasis
prognosticators Increased mitotic index and histology grade HUVOS grading system (low) post
listed) Increased tumor size and percentage chemotherapy
necrosis Increased tumor size
Tumor location: humerus Increased serum alkaline phosphatase
Increased serum alkaline phosphatase Local recurrence
Increased body weight (>40kg)
This table above has been partially adapted from (Morello et al., 2010; Withrow and Wilkins, 2010; Selvarajah
and Kirpensteijn, 20 I0)
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Table 2: Recent advances (2008-2011) in therapeutic approaches for canine osteosarcoma
Therapy or type In vitro models/ Mechanism/ target/ research conclusions Reference(s)
of management clinical subjects
Combination Pilot study on 5 Cytokine-enhanced vaccine and interferon-B plus (Finocchiaro
immune- and dogs with OS suicide gene as combined therapy et al., 20 II)
suicide gene
therapy
Lycopene In vitro models Carotenoid synthesized from plant material (natural (Wakshlag
compound). and Balkman,
Lycopene did not negatively or positively affect 2010)
survival of osteosarcoma cells during doxorubicin
treatment and independently induced apoptosis in the
HMPOS cell line. These findings warrant further in
vitro and in vivo studies into the use of this natural
compound as an adjuvant antiproliferative,
proapoptotic treatment in dogs with osteosarcoma.
Rapamycin In vitro, dogs Targets mTOR pathway. Rapamycin may be safely (Paoloni et al.,
with OS administered to dogs and can yield therapeutic 2010a)
exposures.
Gemcitabine In vitro models, Gemcitabine replaces cytidine, during DNA (McMahon et
dogs with OS replication and targets enzyme ribonucleotide al.,2010);
reductase (RNR) during cell replication. (Rodriguez et
Gemcitabine exhibited biological activity against al.,2010)
canine OSA cell lines in vitro, and a combination of
gemcitabine and carboplatin exhibited synergistic
activity at biologically relevant concentrations.
Aerosol gemcitabine may be useful against
pulmonary metastases of osteosarcoma.
Histone Canine OS Treatment of canine and human OS cell lines with (Wittenburg et
deacetylase xenograft model clinically achievable VPA concentrations resulted in al., 20 lOa);
inhibitor valporic increased histone acetylation but modest anti- (Wittenburg et
acid _Qroliferative effects. al.,2010b)
Sorafenib In vitro models Small molecular inhibitor of several tyrosine kinases (Wolfesberger
: VEGFR, PDGFR and Raf. et al., 20 io)
A significant decrease of neoplastic cells was
observed after incubation.with 0.5-16 microM
sorafenib or with 80-640 microM carboplatin
Bisphosphanates Dogs with OS, in Single-agent pamidronate administered intravenously (Fan et al.,
vitro models with NSAID therapy relieves pain and diminishes 2007,2008
pathologic bone turnover associated with and 2009b);
appendicular OSA in a subset of dogs. Poirier et al.,
Upon pain control, adjuvant pamidronate appears to 2003)
decrease focal bone resorption in the local tumor
microenvironment.
Thoracoscopy Dogs with OS Single case report- thoracoscopy by lateral approach (Dhumeaux
approach to resect to resect lung lesions and
pulmonary Haudiquet,
metastasis 2009)
Satrap latin- Dogs with OS Satraplatin is the first orally bioavailable platinum (Selting, K.A.,
cytotoxic drug and other anti-cancer drug. Well tolerated in tumor-bearing etal.2011)
spontaneous dogs and warrants Phase II clinical trial evaluation.
cancers, in vitro Toxicities noted including dose-limiting
model myelosuppression and mild gastrointestinal toxicity.
HSP90 inhibitor . In vitro models Targets Heat shock protein 90 (McCleese et
(STA-1474) STA-1474 induced tumor regression, caspase-3 al.,2009)
activation and downregulation ofp-MetlMet and p-
Akt/ Akt in OSA xenografts, suggesting that HSP90
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represents a relevant target for therapeutic
intervention in OSA.
In vivo- dogs Completed phase I evaluation ofSTA-1474, as (London, C.A.
withOSAand Prodrug of the Novel HSP90 inhibitor Ganetespib in et aI., 2011)
other dogs with cancer. Toxicities observed primarily
spontaneous gastrointestinal in nature.
cancers
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